US Patent 7749515 Targeted delivery of botulinum toxin to the sphenopalatine ganglion

Patent 7749515 was granted and assigned to Allergan, Inc. on July, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Allergan, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

77495150

Patent Inventor Names

Andrew Blumenfeld0

Date of Patent

July 6, 2010

Patent Application Number

121365030

Date Filed

June 10, 2008

Patent Primary Examiner

‌

Chih-Min Kam

Patent abstract

Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7749515 Targeted delivery of botulinum toxin to the sphenopalatine ganglion

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API